Evolving Challenges in Promoting Cardiovascular Health
Samenvatting
This Annals volume stems from the two–day conference "Evolving Challenges in Promoting Cardiovascular Health" sponsored by The New York Academy of Sciences, "la Caixa" Foundation, and the International Center for Scientific Debate (ICSD), which took place November 4–5, 2011 in Barcelona, Spain. Leading and emerging investigators working on the fields of cardiology, vascular disease, inflammation, metabolic disorders, hematology, imaging, regenerative medicine, stem cell research, epidemiology, and nutrition, among others, address novel issues, current challenges, and future directions in the prevention, treatment, and management of the evolving global epidemic of cardiovascular disease. The papers in this volume explore the promotion of cardiovascular health through molecular biology, clinical pathophysiology, and population research.
NOTE: Annals volumes are available for sale as individual books or as a journal. For information on institutional journal subscriptions, please visit http://ordering.onlinelibrary.wiley.com/subs.asp?ref=1749–6632&doi=10.1111/(ISSN)1749–6632.
ACADEMY MEMBERS: Please contact the New York Academy of Sciences directly to place your order (www.nyas.org). Members of the New York Academy of Science receive full–text access to Annals online and discounts on print volumes. Please visit http://www.nyas.org/MemberCenter/Join.aspx for more information about becoming a member.
Specificaties
Inhoudsopgave
<p>7. Plaque neovascularizationl defense mechanisms, betrayal, or a war in progress<br /> Pedro R. Moreno, Meeranani Purushothaman, and K–Raman Purushothaman</p>
<p>18. LDL–cholesterol versus HDL–cholesterol in the atherosclerotic plaque: inflammatory resolution versus thrombotic chaos<br /> Lina Badimon and Gemma Vilahur</p>
<p>33. Evolving role of molecular imaging for new understanding: targeting myofibroblasts to predict remodeling<br /> Hans J. de Haas, Susanne W. van den Borne, Hendrikus H. Boersma, Riemer H.J.A. Slart, Valentin Fuster, and Jagat Narula</p>
<p>42. Molecular targets in heart failure gene therapy: current controversies and translational perspectives<br /> Victor Kairouz, Larissa Lipskaia, Roger J. Hajjar, and Elie R. Chemaly</p>
<p>51. Engineered arterial models to correlate blood flow to tissue biological response<br /> Jordi Martorell, Pablo Santomá, José J. Molins, Andrés A. García–Granada, José A. Bea, Elazer R. Edelman, and Mercedes Balcells</p>
<p>57. A bird s–eye view of cell therapy and tissue engineering for cardiac regeneration<br /> Carolina Soler–Botija, Juli R. Bagó, and Antoni Bayes–Genis</p>
<p>66. Umbilical cord blood for cardiovascular cell therapy: from promise to fact<br /> Santiago Roura, Josep–Maria Pujal, and Antoni Bayes–Genis</p>
<p>71. Heart repair: from natural mechanisms of cardiomyocyte production to the design of new cardiac therapies<br /> Silvia Martin–Puig, Valentín Fuster, and Miguel Torres</p>
<p>82. Energy metabolism plasticity enables stemness programs<br /> Clifford D.L. Folmes, Timothy J. Nelson, Petras P. Dzeja, and Andre Terzic</p>
<p>90. The future: therapy of myocardial protection<br /> David Sanz–Rosa, Jaime Garcia–Prieto, and Borja Ibanez</p>
<p>99. The links between complex coronary disease, cerebrobascular disease, and degenerative brain disease<br /> Jason C. Kovacic, Jose M. Castellano, and Valentin Fuster</p>
<p>106. Optimal lipid targets for the new era of cardiovascular prevention<br /> Vimal Ramjee, danny J. Eapen, and Laurence S. Sperling</p>
<p>115. Controversies in blood pressure goal guidelines and masked hypertension<br /> Robert A. Phillips</p>
<p>123. Evolving diagnostic and prognostic imaging of the various cardiomyopathies<br /> Javier Sanz</p>
<p>131. The evolving landscape of quality measurement for heart failure<br /> Ashley A. Fitzgerald, Larry A. Allen, and Frederick A. Masoudi</p>
<p>140. Atrial Fibrillation, Stock, and quality of life<br /> Jason S. Chinitz, Jose M. Castellano, Jason C. Kovacic, and Valentin Fuster</p>
<p>151. Transcatheter aortic valve implantation and cerebrovascular events: the current state of the art<br /> Brian G. Hynes and Josep Rodés–Cabau</p>
<p>164. Are we ignoring the dilated thoracic aortia?<br /> Jose M. Castellano, Jason C. Kovacic, Javier Sanz, and Valentin Fuster</p>
<p>175. Corrigendum</p>